Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide for Myelodysplastic Syndromes: Efficacy, Safety, Cardiac Changes, and Quality of Life (QoL-ESC RevMDS)
2008-000547-34Phase 2Completed
- Sponsor
- Qol-one
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in 5q deletion syndrome, sponsored by Qol-one. Primary endpoint: Change in quality of life scores (QoL-E). Started Jun 2008; status: completed.
02
Drugs
lenalidomide
03
Conditions
5q deletion syndrome
Beyond the preview
Go deeper on 2008-000547-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000547-34.